{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:15:02Z","timestamp":1793481302361,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018405","name":"Adolf Leuze Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A loss of the trimethylation of lysine 27 of histone H3 (H3K27me3) in meningioma has been recently suggested as an adjunct to identify subsets of higher risk of recurrence. The aim of the present study was to assess the prognostic value of H3K27 histone trimethylation and its potential clinical utility in the \u201cT\u00fcbingen meningioma cohort.\u201d<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients who underwent meningioma resection between October 2003 and December 2015 at the University Hospital T\u00fcbingen were included. Immunohistochemical stainings for H3K27me3 and the proliferation marker MIB1 were assessed and correlated with clinical parameters using univariate and multivariate Cox regressions as well as Pearson's chi-squared and log-rank test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 1268 meningiomas were analyzed with a female to male ratio of 2.6 and a mean age of 58.7 years (range 8.3\u201391.0). With 163 cases lost to follow up, 1103 cases were available for further analysis with a mean follow-up of 40.3 months (range 1.1\u2013186.3). Male gender, younger age, intracranial tumor localization, progressive tumor, subtotal resection, higher WHO grade, increased MIB1 rate, and loss of H3K27me3 were significant negative prognostic factors in the univariate analysis. H3K27me3 status and all other prognostic factors, except age and tumor location, remained significant in the multivariate model. Furthermore, adjuvant radiotherapy was an independent positive prognostic factor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Loss of H3K27me3 combined with MIB1 labeling index are independent prognostic factors in meningioma. These data from the T\u00fcbingen meningioma cohort support the clinical utility of H3K27me3 immunohistochemical staining in meningioma and its integration into the routine histopathological workup.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa303","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T08:05:15Z","timestamp":1608365115000},"page":"1273-1281","source":"Crossref","is-referenced-by-count":50,"title":["H3K27me3 loss indicates an increased risk of recurrence in the T\u00fcbingen meningioma cohort"],"prefix":"10.1093","volume":"23","author":[{"given":"Felix","family":"Behling","sequence":"first","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fodi","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Gepfner-Tuma","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital T\u00fcbingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kaltenbach","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital T\u00fcbingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Renovanz","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital T\u00fcbingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Paulsen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), DKFZ Partner Site T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Radiation Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Skardelly","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Honegger","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Consortium on Meningiomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6209","authenticated-orcid":false,"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), DKFZ Partner Site T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neuropathology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital T\u00fcbingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), DKFZ Partner Site T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Cluster of excellence (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"2021080214181611600_CIT0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"issue":"Suppl 1","key":"2021080214181611600_CIT0002","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","article-title":"Advances in multidisciplinary therapy for meningiomas","volume":"21","author":"Brastianos","year":"2019","journal-title":"Neuro Oncol."},{"issue":"9","key":"2021080214181611600_CIT0003","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021080214181611600_CIT0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","article-title":"Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539","volume":"129","author":"Rogers","year":"2018","journal-title":"J Neurosurg."},{"issue":"6","key":"2021080214181611600_CIT0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2021080214181611600_CIT0006","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2021080214181611600_CIT0007","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2021080214181611600_CIT0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell."},{"issue":"5","key":"2021080214181611600_CIT0009","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/15592294.2016.1278095","article-title":"Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies","volume":"12","author":"Maury","year":"2017","journal-title":"Epigenetics."},{"key":"2021080214181611600_CIT0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.acr.2016.05.001","article-title":"H3K27 methylation: a focal point of epigenetic deregulation in cancer","volume":"131","author":"Nichol","year":"2016","journal-title":"Adv Cancer Res."},{"issue":"2","key":"2021080214181611600_CIT0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00018-017-2596-8","article-title":"Orchestration of H3K27 methylation: mechanisms and therapeutic implication","volume":"75","author":"Pan","year":"2018","journal-title":"Cell Mol Life Sci."},{"issue":"3","key":"2021080214181611600_CIT0012","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10014-015-0221-9","article-title":"Involvement of epimutations in meningioma","volume":"32","author":"Venza","year":"2015","journal-title":"Brain Tumor Pathol."},{"issue":"6","key":"2021080214181611600_CIT0013","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2021080214181611600_CIT0014","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnen\/nlaa038","article-title":"Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study","volume":"79","author":"Gauchotte","year":"2020","journal-title":"J Neuropathol Exp Neurol."},{"issue":"4","key":"2021080214181611600_CIT0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","article-title":"Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis","volume":"91","author":"Mirian","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"2021080214181611600_CIT0016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021080214181611600_CIT0017","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021080214181611600_CIT0018","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm.2305","article-title":"Cancer epigenetics reaches mainstream oncology","volume":"17","author":"Rodr\u00edguez-Paredes","year":"2011","journal-title":"Nat Med."},{"issue":"3","key":"2021080214181611600_CIT0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet."},{"issue":"1","key":"2021080214181611600_CIT0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-019-03278-w","article-title":"Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas","volume":"145","author":"Li","year":"2019","journal-title":"J Neurooncol."},{"issue":"1","key":"2021080214181611600_CIT0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/nox149","article-title":"Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location","volume":"20","author":"Karremann","year":"2018","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021080214181611600_CIT0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-019-03247-3","article-title":"H3K27 trimethylation loss in malignant peripheral nerve sheath tumor: a systematic review and meta-analysis with diagnostic implications","volume":"144","author":"Lu","year":"2019","journal-title":"J Neurooncol."},{"issue":"5","key":"2021080214181611600_CIT0023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","article-title":"Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome","volume":"134","author":"Panwalkar","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2021080214181611600_CIT0024","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.cell.2020.04.047","article-title":"Metabolic regulation of the epigenome drives lethal infantile ependymoma","volume":"181","author":"Michealraj","year":"2020","journal-title":"Cell"},{"issue":"1","key":"2021080214181611600_CIT0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa303\/36238558\/noaa303.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/8\/1273\/39535664\/noaa303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/8\/1273\/39535664\/noaa303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T14:46:17Z","timestamp":1627915577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/8\/1273\/6046432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa303","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,12,23]]}}}